200 NBTXR3 nanoparticle with immunoradiation improves survival and generates long-term anti-tumor memory in an anti-PD1 resistant murine lung cancer model

200 NBTXR3 nanoparticle with immunoradiation improves survival and generates long-term anti-tumor memory in an anti-PD1 resistant murine lung cancer model

Bibliographic Details
Main Authors:	James Welsh, Sébastien Paris, Hampartsoum Barsoumian, Yun Hu, Chike Abana, Saumil Gandhi, Quynh Nguyen, Maria Cortez
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model
by: Yun Hu, et al.
Published: (2021-12-01)

575 Dual blockade of LAG3 and TIGIT improves the treatment efficacy of a nanoparticle-mediated immunoradiation in anti-PD1 resistant lung cancer in mice
by: James Welsh, et al.
Published: (2021-11-01)

NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model
by: Yun Hu, et al.
Published: (2022-11-01)

396 Overcoming resistance to anti-PD-1 with tumor agnostic NBTXR3: from bench to bed side
by: Ping Zhang, et al.
Published: (2020-11-01)

1092 Induction of lysosomal membrane permeabilization by radiotherapy-activated NBTXR3 nanoparticles
by: Sébastien Paris, et al.
Published: (2023-11-01)

Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer
by: Yun Hu, et al.
Published: (2022-09-01)

Radiation and Anti-Cancer Vaccines: A Winning Combination
by: Alexandra Cadena, et al.
Published: (2018-01-01)

Radiotherapy-activated NBTXR3 nanoparticles modulate cancer cell immunogenicity and TCR repertoire
by: Audrey Darmon, et al.
Published: (2022-06-01)

Radiotherapy-activated NBTXR3 nanoparticles promote ferroptosis through induction of lysosomal membrane permeabilization
by: Jordan Da Silva, et al.
Published: (2024-01-01)

1090 Enhancing DNA damage and micronuclei production in human cancer cell lines through radiotherapy-activated NBTXR3 nanoparticles
by: Sébastien Paris, et al.
Published: (2023-11-01)

Pulsed radiotherapy to mitigate high tumor burden and generate immune memory
by: Duygu Sezen, et al.
Published: (2022-10-01)

740 Radiotherapy-activated NBTXR3 nanoparticles Increase CD8+ T cell infiltration and diversity in tumors, and modulate the immunopeptidome of cancer cells
by: Ping Zhang, et al.
Published: (2021-11-01)

Penfigoide anti p-200 Anti-p200 pemphigoid
by: T Zarowsky
Published: (2011-06-01)

Pulsed Radiation Therapy to Improve Systemic Control of Metastatic Cancer
by: Kewen He, et al.
Published: (2021-08-01)

Potential contribution of anti-p200 autoantibodies to mucosal lesions in anti-p200 pemphigoid
by: Yangmin Gao, et al.
Published: (2023-01-01)

NBTXR3 Radiotherapy-Activated Functionalized Hafnium Oxide Nanoparticles Show Efficient Antitumor Effects Across a Large Panel of Human Cancer Models
by: Zhang P, et al.
Published: (2021-04-01)

Anti-glucocorticoid-induced Tumor Necrosis Factor–Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects
by: Jonathan E. Schoenhals, et al.
Published: (2018-09-01)

Imaging Features of Intratumoral Injection of NBTXR3 for Head and Neck Squamous Cell Carcinoma Lymph Node Metastases
by: Daniel Thomas Ginat, et al.
Published: (2022-09-01)

Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model
by: Soyeon Lim, et al.
Published: (2023-01-01)

Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma
by: John Choi, et al.
Published: (2021-01-01)

4-1BB Signaling in Conventional T Cells Drives IL-2 Production That Overcomes CD4+CD25+FoxP3+ T Regulatory Cell Suppression.
by: Hampartsoum B Barsoumian, et al.
Published: (2016-01-01)

High Plus Low Dose Radiation Strategy in Combination with TIGIT and PD1 Blockade to Promote Systemic Antitumor Responses
by: Hampartsoum B. Barsoumian, et al.
Published: (2022-01-01)

Pathogenicity of autoantibodies in anti-p200 pemphigoid.
by: Katerina Vafia, et al.
Published: (2012-01-01)

Adenosine A2a receptor inhibition increases the anti-tumor efficacy of anti-PD1 treatment in murine hepatobiliary cancers
by: Yuta Myojin, et al.
Published: (2024-01-01)

Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers
by: Camilla Heiniö, et al.
Published: (2022-08-01)

Anti-p200 pemphigoid mimicking erythema multiforme
by: Lucile Séméria, MD, et al.
Published: (2022-03-01)

Anti-p200 Pemphigoid: A Systematic Review
by: Khalaf Kridin, et al.
Published: (2019-10-01)

Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression
by: Philip Vitorino, et al.
Published: (2021-01-01)

New insights into the anti-PD-L1 and anti-PD-1 reagents in cancer therapy
by: Cheng Chen, et al.
Published: (2016-04-01)

HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy
by: Shaima Salman, et al.
Published: (2022-05-01)

Bone morphogenetic proteins, activins, and growth and differentiation factors in tumor immunology and immunotherapy resistance
by: Shonik Ganjoo, et al.
Published: (2022-10-01)

Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies
by: Jihane Boustani, et al.
Published: (2021-09-01)

Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies
by: Giuseppe Bellastella, et al.
Published: (2021-08-01)

Cyclophosphamide depletes tumor infiltrating T regulatory cells and combined with anti-PD-1 therapy improves survival in murine neuroblastoma
by: Emily R. Webb, et al.
Published: (2022-09-01)

Hereditary diffuse gastric cancer therapeutic roadmap: current and novel approaches in a nutshell
by: Fadi E. El Rami, et al.
Published: (2020-10-01)

Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma
by: Nusrat Jahan, et al.
Published: (2019-05-01)

The RadScopal Technique as an Immune Adjuvant to Treat Cancer
by: Hampartsoum B. Barsoumian, et al.
Published: (2023-02-01)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
by: Giuseppe Luigi Banna, et al.
Published: (2020-07-01)

Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
by: Andrea Botticelli, et al.
Published: (2021-08-01)

Anti-Fibrotic and Anti-Inflammatory Role of NO-Sensitive Guanylyl Cyclase in Murine Lung
by: Nils Englert, et al.
Published: (2023-07-01)